Predicting stringent QuantiFERON-TB Gold Plus conversions in contacts of tuberculosis patients.
Interferon-gamma release assay
QuantiFERON-TB Gold plus
Stringent conversion
Tuberculosis contacts
Journal
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
ISSN: 1995-9133
Titre abrégé: J Microbiol Immunol Infect
Pays: England
ID NLM: 100956211
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
15
03
2023
revised:
23
07
2023
accepted:
31
07
2023
medline:
9
10
2023
pubmed:
15
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
To assess associations between disease severity in index TB patients and QuantiFERON-TB Gold Plus (QFT-Plus) results in contacts, and predictors for QFT-Plus conversion in contacts over 6-12 months. TB patients (n = 295) and the contacts (n = 1051) were enrolled during 2018-2021 with QFT-Plus performed at baseline and months 6 and 12. A strong CD8 response was defined as TB2 interferon gamma (IFN-γ) response minus TB1 >0.6 IU/ml and stringent conversion as change from QFT-plus negative to high-positive QFT-Plus (TB1 or TB2 IFN-γ responses >0.7 IU/ml). Contacts with index TB patients with sputum smear >1+ was associated with positive QFT-Plus compared to those without (p < 0.001). Contacts with index TB patients with bilateral lung disease were more likely to have strong CD8 responses than those without (p = 0.038). QFT-Plus stringent conversion occurred in 9.7% of contacts over 6-12 months. A TB1 IFN-γ response ≥0.03 IU/ml combined with a TB2 ≥0.06 IU/ml was predictive of a 19-fold increased risk for QFT-Plus stringent conversion in contacts (odd ratio 19.565 [8.484-45.116], p < 0.001). Bacterial burden and bilateral lung disease of index TB patients were associated with positive QFT-Plus and strong CD8 responses in contacts. TB1 and TB2 IFN-γ responses were synergistically predictive of stringent conversion in contacts.
Identifiants
pubmed: 37580184
pii: S1684-1182(23)00150-0
doi: 10.1016/j.jmii.2023.07.014
pmc: PMC10604336
mid: NIHMS1935965
pii:
doi:
Substances chimiques
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1073-1083Subventions
Organisme : NIAID NIH HHS
ID : R01 AI137681
Pays : United States
Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Références
Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S25-S26
pubmed: 28043588
Medicine (Baltimore). 2015 Oct;94(43):e1870
pubmed: 26512600
J Microbiol Immunol Infect. 2016 Aug;49(4):575-83
pubmed: 26694909
J Infect Dis. 2000 May;181(5):1846-9
pubmed: 10823799
Eur J Immunol. 2000 Dec;30(12):3689-98
pubmed: 11169412
Lancet Infect Dis. 2017 Nov;17(11):1190-1199
pubmed: 28827142
Am J Respir Crit Care Med. 2020 Apr 15;201(8):984-991
pubmed: 31825645
Int J Tuberc Lung Dis. 2007 Mar;11(3):282-8
pubmed: 17352093
Int J Tuberc Lung Dis. 2009 Jan;13(1):84-92
pubmed: 19105884
Eur Respir J. 2019 Sep 12;54(3):
pubmed: 31221810
Am J Respir Crit Care Med. 2017 Sep 1;196(5):638-648
pubmed: 28737960
J Infect. 2019 Apr;78(4):299-304
pubmed: 30707912
Am J Epidemiol. 1974 Feb;99(2):131-8
pubmed: 4810628
Am J Epidemiol. 2014 Jan 15;179(2):216-25
pubmed: 24142915
Clin Infect Dis. 2020 Apr 10;70(8):1562-1572
pubmed: 31127813
Medicine (Baltimore). 2015 Sep;94(39):e1628
pubmed: 26426648
Respir Med. 2021 Aug-Sep;185:106508
pubmed: 34171790
Clin Infect Dis. 2011 Apr 15;52(8):1031-7
pubmed: 21460320
Eur Respir J. 2016 Nov;48(5):1411-1419
pubmed: 27390280
Clin Chem Lab Med. 2023 May 25;61(12):2067-2075
pubmed: 37221870
Trop Med Infect Dis. 2022 Sep 30;7(10):
pubmed: 36288019